Huafeng Wang

13PUBLICATIONS
25CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 27, 2026
Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

|Jun 02, 2026
Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.

|Mar 19, 2026
Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia.

Ge Liu, Yile Zhou, Yinjun Lou

|Jul 22, 2025
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia.

Bingqian Jiang, Hongyan Tong, Min Yang

|Mar 16, 2025
Characteristics and predictors of central nervous system relapse in newly diagnosed acute promyelocytic leukemia in the era of arsenic: a 13-year monocenter cohort study.

Bingqian Jiang, Hongyan Tong, Haitao Meng

|Mar 13, 2025
Comparison of subcutaneous injection versus intravenous infusion of cytarabine for induction therapy in adult acute myeloid leukemia.

Huafeng Wang, Shanshan Suo, Dengju Li

Pageof 3

Frequent Collaborators

11 joint publications

Jie Jin

7 joint publications

Hongyan Tong

4 joint publications

Yinjun Lou

3 joint publications

Yi Zhang